Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS)
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
At a glance
- Drugs CK 0801 (Primary)
- Indications Guillain-Barre syndrome
- Focus Adverse reactions
- 06 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 06 Feb 2019 Status changed from not yet recruiting to suspended due to Pending contract negotiations..
- 10 Dec 2018 Status changed from planning to not yet recruiting.